Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 1

Hypokalemia secondary to capecitabine: a hidden toxicity?

Authors Muhammad Wasif Saif, Mohammad Houman Fekrazad, Leslie Ledbetter, Robert B Diasio

Published 15 March 2007 Volume 2007:3(1) Pages 177—180

Muhammad Wasif Saif1, Mohammad Houman Fekrazad2, Leslie Ledbetter3, Robert B Diasio3

1Yale University School of Medicine, New Haven, CT; 2Carraway Methodist Medical Center, Birmingham, AL; 3University of Alabama at Birmingham, AL, USA Presented at the Annual Meeting of ASCO, Orlando, FL in 2005.

Background: Hyopkalemia is a listed toxicity in the capecitabine (Xeloda®; Roche, Nutley, NJ) package insert. However, the incidence and severity of this toxicity is not known.

Methods: We performed a retrospective evaluation of hypokalemia in 77 patients, who received capecitabine for gastrointestinal malignancies between April 2002 and November 2004. Hypokalemia was defined as K+ level <3.2 mEq/L. Patients with documented ≥grade 2 vomiting or diarrhea, diuretics, hypomagnesemia, hypokalemia, renal insufficiency, endocrine dysfunction (thyroid, adrenal, diabetic) were excluded. Hypokalemic patients were graded as: mild (grade 1: 3.0–3.2 mEq/L), moderate (grade 3: 2.5–2.9 mEq/L) and severe (grade 4: <2.5 mEq/L). We also reviewed the literature.

Results: Fifty-four patients met the above criteria. The most common cause of exclusion was ≥ grade 2 diarrhea (23 patients; 30%). Overall, hypokalemia was encountered in 11 patients (20.4%). Among hypokalemic patients, 8 patients (73%) presented with mild/grade 1 hypokalemia (3.0–3.2 mEq/L), 2 patients (18.18%) with moderate/grade 3 hypokalemia (2.5–2.9 mEq/L) and 1 patient (9.09%) with severe/grade 4 hypokalemia (<2.5 mEq/L) 8 (73%). Dose of capecitabine ranged between 1000–2000 mg/m2. Hypokalemia occurred after an average of 83.7 days of capecitabine administration. No cardiac or neuromuscular complications were noticed. Replacement of K+ was required in 6 patients (2 intravenous and 4 oral), while 2 patients (3.7%) required oral supplements >4 weeks. No patient had to stop capecitabine due to hypokalemia. One patient had persistent hypokalemia even after stopping capecitabine. Normalization of K+ levels was achieved in 91% of patients. Four patients were on K+ sparing diuretics for ascites and never presented with hypokalemia. Mean urine K+ was 28 mEq/L. Only 5.5% patients had ≥grade 3 hypokalemia in our study compared with 2% and 14% in two other studies.

Conclusions: Although diarrhea being the most common cause of hypokalemia in patients on capecitabine, we postulate that hypokalemia may also be related to the effect of capecitabine on renal tubules suggested by the urine K+ in some patients. Due to potential complications, hypokalemia in patients on capecitabine deserves special diagnostic and therapeutic attention.

Keywords: 5-FU, capecitabine (Xeloda), hypokalemia, renal loss, potassium, colon cancer

Download Article [PDF] 

Readers of this article also read:

Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK

Gelhorn HL, Poon JL, Davies EW, Paczkowski R, Curtis SE, Boye KS

Patient Preference and Adherence 2015, 9:1611-1622

Published Date: 9 November 2015

Pulmonary hypertension: diagnostic and therapeutic challenges

Bazan IS, Fares WH

Therapeutics and Clinical Risk Management 2015, 11:1221-1233

Published Date: 17 August 2015

Prediction and prevention of the first psychotic episode: new directions and opportunities

Piras S, Casu G, Casu MA, Orrù A, Ruiu S, Pilleri A, Manca G, Marchese G

Therapeutics and Clinical Risk Management 2014, 10:241-253

Published Date: 28 March 2014

Poly (ε-caprolactone) nanofibrous ring surrounding a polyvinyl alcohol hydrogel for the development of a biocompatible two-part artificial cornea

Bakhshandeh H, Soleimani M, Shah Hosseini S, Hashemi H, Shabani I, Shafiee A, Behesht Nejad AH, Erfan M, Dinarvand R, Atyabi F

International Journal of Nanomedicine 2011, 6:1509-1515

Published Date: 14 July 2011

Optimal timing for antihypertensive dosing: focus on valsartan

Ramón C Hermida, Diana E Ayala, Carlos Calvo

Therapeutics and Clinical Risk Management 2007, 3:119-131

Published Date: 15 March 2007